Skip to the content
Acrivon
  • About
  • People
  • Science & Publications
    • Science
    • Publications & Posters
  • Pipeline
  • Clinical Trials
  • Investors & Media
    • Overview
    • News & Events
      • News Releases
      • Events & Presentations
    • Stock Info
      • Stock Quote & Chart
      • Analyst Coverage
    • Governance
      • Documents & Charters
      • Senior Leadership
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Contact & Careers
News & Publications
Featured News
06. 27. 2022

Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an…
See more
Acrivon Therapeutics
06. 22. 2022

Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368

Acrivon Therapeutics
04. 20. 2022

Acrivon Therapeutics Announces the Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives

Acrivon Therapeutics
03. 16. 2022

Acrivon Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

Acrivon Therapeutics
12. 08. 2021

Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders

Acrivon Therapeutics
11. 29. 2021

Acrivon Therapeutics to Present at the Evercore ISI HealthCONx Conference

Acrivon Therapeutics
11. 11. 2021

Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline

Acrivon Therapeutics
06. 29. 2021

Acrivon Therapeutics Launches to Advance Clinical Oncology Pipeline Leveraging its Groundbreaking Precision Proteomics Platform

Events & Presentations

Oppenheimer 32nd Annual Healthcare Conference
03. 17. 2022

Acrivon Presentation

Evercore ISI 4th Annual HealthCONx Conference
11. 30. 2021

Acrivon presentation (Live 8am ET)

Media Highlights

Endpoints News
11. 11. 2021

Acrivon bags a megaround to advance an old Eli Lilly program, 5 months after launch. Is an IPO far behind?

Fierce Biotech
11. 11. 2021

Acrivon Therapeutics secures $100M to give Eli Lilly cancer drug another try, fund 2 solid tumor candidates

Boston Business Journal
11. 11. 2021

With $100M, startup to bring Lilly-licensed drug into trials

Precision Oncology News
11. 11. 2021

Acrivon Therapeutics Raises $100M in Series B Funding

Biospace
11. 11. 2021

Acrivon Nets $100 Million and Licenses Cast-Off Lilly Oncology Drug

Biocentury
11. 11. 2021

Crossovers back Acrivon in $100M series B

Endpoints News
06. 29. 2021

Can a small band of biopharma players succeed where Eli Lilly failed? They’re taking a shot

BioCentury
06. 29. 2021

Acrivon debuts with Lilly DDR inhibitor to test proteomics-based companion diagnostics platform

Boston Business Journal
06. 29. 2021

Precision medicine startup launches with Eli Lilly deal and $20M in VC funds

Precision Oncology News
06. 29. 2021

Eli Lilly Grants Acrivon Therapeutics Worldwide License to Develop DNA Damage Inhibitor Prexasertib

company logo
  • About
  • People
  • Science & Publications
  • Pipeline
  • Clinical Trials
  • Investors & Media
  • Contact & Careers
© 2025 Acrivon Therapeutics. All rights reserved.

  • Terms of Use
  • Privacy Statement
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
wordpress_logged_in_*SessionThis cookie is used to indicate when you are logged in
wordpress_test_cookiesessionThis cookie is used to read if cookies can be placed
wp-settings-time-*1 yearThis cookie is used to store user preferences

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

CookieDurationDescription
_ga2 yearsThis cookie is used to store and count pageviews by Google Analytics
_ga_*1 yearThis cookie is used to store and count pageviews by Google Analytics

Save & Accept
Powered by